YM Bioscience reports Phase II data for nimotuzumab in metastatic colorectal cancer
Overall Survival And Disease Control Outcomes, Coupled With Low Toxicity, Support The Continued Development Of The EGFR Antibody In Patients With Colorectal Cancer
06-Aug-2008 -
YM BioSciences Inc. announced preliminary results obtained from its open-label, Phase II study (YMB1000-015) of nimotuzumab in patients with irinotecan-refractory, metastatic colorectal cancer (mCRC). The data are based on 58 evaluable patients of the 61 enrolled in the trial. The trial was ...
antibodies
colorectal cancer
metastatic colorectal cancer
+1